clinical trial · NCT06898060
To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture
Qilu Pharmaceutical Co., Ltd.·phase3·not yet recruiting·n = 282
Postmenopausal Women With OsteoporosisQLG2128Teriparatide Injection
brief summary
The purpose of this study is to evaluate the efficacy and safety of QLG2128 in the treatment of postmenopausal women with osteoporosis and at high risk of fracture.
started
Jun 1, 2025
primary completion
May 1, 2027
completion
May 1, 2027
last updated
Mar 27, 2025
official title
A Multicenter, Randomized, Open-label, Parallel Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol